{"result": "(\"entity\"<|>Lactobacillus GG<|>ORGANIZATION<|>Lactobacillus GG is a strain of probiotic bacteria that is believed to confer health benefits when administered in adequate doses.)\n##\n(\"entity\"<|>Acetato de Megestrol<|>ORGANIZATION<|>Acetato de Megestrol is an orexigenic medication used to improve caloric intake and weight in patients with nutritional deficiencies.)\n##\n(\"entity\"<|>Ciproheptadina<|>ORGANIZATION<|>Ciproheptadina is an orexigenic drug evaluated for its potential to enhance appetite and weight gain in patients.)\n##\n(\"entity\"<|>RTFQ<|>ORGANIZATION<|>RTFQ refers to a protein whose function is being restored through various medications aimed at treating specific genetic mutations.)\n##\n(\"entity\"<|>Ensayos Clínicos<|>EVENT<|>Ensayos Clínicos refers to clinical trials that are currently underway to test new drugs aimed at restoring protein function in patients.)\n##\n(\"entity\"<|>España<|>GEO<|>España is the country where the first drug (ivacaftor) capable of correcting the defect of specific mutations has been commercialized.)\n##\n(\"relationship\"<|>Lactobacillus GG<|>FQ<|>Lactobacillus GG may help reduce inflammation markers in patients with cystic fibrosis<|>4)\n##\n(\"relationship\"<|>Acetato de Megestrol<|>FQ<|>Acetato de Megestrol is used as a treatment to improve caloric intake in patients with cystic fibrosis<|>6)\n##\n(\"relationship\"<|>Ciproheptadina<|>FQ<|>Ciproheptadina is evaluated for its potential to enhance appetite in patients with cystic fibrosis<|>6)\n##\n(\"relationship\"<|>RTFQ<|>IVACAFTOR<|>RTFQ is the protein that ivacaftor aims to correct in patients with specific mutations<|>8)\n##\n(\"relationship\"<|>Ensayos Clínicos<|>IVACAFTOR<|>Clinical trials are being conducted to test the efficacy of ivacaftor and other drugs aimed at restoring protein function<|>7)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: NP basadas únicamente en glucosa pueden incrementar la producción de CO2, por lo que se recomienda que la composición de la parenteral debe contener lípidos (al menos en un 35% de las calorías no proteicas y como máximo hasta un 65 %) . En NP son también aplicables las recomendaciones anteriormente detalladas de la SEMICYUC y SENPE.\n\n## 8. Otros tratamientos en el abordaje nutricional en la fibrosis quística\n\nComo tratamiento coadyuvante en la desnutrición se han empleado orexígenos con el objetivo de mejorar la ingesta calórica, así como el peso y la calidad de vida. Tanto el acetato de megestrol como la ciproheptadina han sido evaluados a corto plazo (6 meses), objetivándose mejoras en el peso y en el apetito. No obstante, dados sus posibles efectos secundarios y la calidad baja a moderada de las pruebas que lo sus-\n\ntentan, no es posible realizar recomendaciones para su uso 102.\n\nEl empleo de probióticos (bacterias vivas que confieren beneficios en la salud del huésped suministrados a dosis adecuadas, por ejemplo la cepa Lactobacillus GG) podrían reducir los marcadores de inflamación y las reagudizaciones. No obstante, los datos son muy preliminares y es necesario confirmarlos con pruebas de mejor calidad103.\n\nEn los últimos años se han comercializado fármacos cuyo objetivo es la restauración de la función de la proteína RTFQ104. Dentro del desarrollo de los fármacos reparadores de la proteína RTFQ, se han identificado tres grupos principales. En primer lugar, los supresores del codón de parada prematuro (mutación de clase 1). Estos fármacos consiguen que no se identifique este codón de parada prematuro, por lo que la proteína puede seguir su síntesis al completo. En segundo lugar, los denominados fármacos correctores del RTFQ. Estos fármacos están diseñados para corregir el tráfico de la proteína con defectos en el plegamiento (mutaciones de clase 2) hasta la membrana celular, donde podría hacer su función casi con normalidad. En tercer lugar, los denominados potenciadores del RTFQ. Estos fármacos tienen por diana la proteína RTFQ que está en la superficie celular, con objeto de mejorar su función. Los fármacos potenciadores pueden actuar por tanto sobre las mutaciones de clases III a VI. Actualmente están en investigación numerosas moléculas con uno u otro mecanismo, llegando ya a comercializarse una de ellas. En la actualidad ya se dispone en España del primer fármaco (ivacaftor) capaz de corregir el defecto de las mutaciones Gly551ASP y otras similares, estando prevista la comercialización a corto plazo de nuevos fármacos (o combinaciones de varios, como por ejemplo, ivacaftor-lumacaftor) modificadores de la proteína. Además, están en marcha numerosos ensayos clínicos con moléculas que pretenden restaurar la función. En pacientes > 2 años con la mutación Gly551Asp (de clase III) ivacaftor ha demostrado, además de aumentar significativa y clínicamente la función pulmonar, mejorar el estado nutricional, incrementando el peso tanto en sujetos mayores como menores de 20 años (aproximadamente entre 3 y 5 kg, respectivamente). Además, parece que podría mejorar la secreción de insulina e incluso la absorción de la grasa. Por tanto, se han abierto campos de investigación muy sugerentes que pueden aportar sus frutos en los próximos años a nivel multisistémico105.\n\n## 9. Resumen y conclusiones\n\nLa prevalencia de desnutrición en FQ, EPOC y BQ es elevada, aunque muy variable según los estudios. La detección de la misma debe realizarse mediante la combinación de diferentes métodos, en función de\n---\n574      BLOQUE: PATOLOGÍAS ESPECÍFICAS\n\nla disponibilidad de los mismos (historia clínica, encuesta dietética, IMC, antropometría, dinamometría de mano, impedanciometría, DEXA, test de la marcha, determinación de proteínas viscerales, etc.), siendo recomendable la estimación de la masa magra y/o su funcionalidad.\n\nEl empeoramiento del estado nutricional guarda una relación directa con el descenso de los parámetros de función pulmonar, y se ha propuesto como un factor predictor de morbilidad e incluso de mortalidad en personas con FQ, BQ y EPOC, independientemente del grado de disfunción pulmonar.\n\nEn los pacientes con FQ se recomienda que la ingesta habitual aporte entre el 120 y 150% de las calorías recomendadas y que contenga alto contenido en grasas. Si no consiguen alcanzar o mantener los objetivos nutricionales previstos con las modificaciones de la dieta, se pueden ad\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>SEMICYUC<|>ORGANIZATION<|>SEMICYUC is a medical society that provides guidelines and recommendations for nutritional approaches in clinical settings.)\n##\n(\"entity\"<|>SENPE<|>ORGANIZATION<|>SENPE is a professional society focused on nutrition and metabolism, offering recommendations for nutritional support in various medical conditions.)\n##\n(\"entity\"<|>IVACAFTOR<|>ORGANIZATION<|>Ivacaftor is a medication designed to correct the function of the RTFQ protein in patients with specific mutations, improving lung function and nutritional status.)\n##\n(\"entity\"<|>Gly551ASP<|>EVENT<|>Gly551ASP is a specific mutation that affects the function of the RTFQ protein, targeted by the medication ivacaftor.)\n##\n(\"entity\"<|>FQ<|>GEO<|>FQ refers to cystic fibrosis, a genetic disorder that affects the lungs and digestive system, leading to nutritional challenges.)\n##\n(\"entity\"<|>EPOC<|>GEO<|>EPOC refers to chronic obstructive pulmonary disease, a progressive lung disease that can lead to nutritional deficiencies.)\n##\n(\"entity\"<|>BQ<|>GEO<|>BQ refers to bronchiectasis, a condition characterized by the abnormal dilation of the bronchi, often associated with nutritional issues.)\n##\n(\"relationship\"<|>IVACAFTOR<|>Gly551ASP<|>Ivacaftor is specifically designed to correct the defect caused by the Gly551ASP mutation in the RTFQ protein<|>8)\n##\n(\"relationship\"<|>FQ<|>EPOC<|>Both FQ and EPOC are conditions that can lead to significant nutritional challenges and require careful management<|>5)\n##\n(\"relationship\"<|>FQ<|>BQ<|>FQ and BQ are both respiratory conditions that can impact nutritional status and require specific dietary considerations<|>5)\n##\n(\"relationship\"<|>EPOC<|>BQ<|>EPOC and BQ are both chronic lung diseases that can lead to malnutrition and require nutritional interventions<|>5)\n##\n(\"relationship\"<|>SEMICYUC<|>SENPE<|>SEMICYUC and SENPE both provide guidelines and recommendations for nutritional support in clinical settings<|>6)\n<|COMPLETE|>"}]}